… studies of gefitinib therapy in patients with advanced non–small-cell lung cancer and
EGFR … We then undertook a phase 3 study comparing gefitinib and standard carboplatin–paclitaxel …

… with EGFR-mutant, gefitinib-responsive, advanced non–small-cell lung cancer who had a …
during treatment with gefitinib. The DNA sequence of the EGFR gene in his tumor biopsy …

… of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor
mutations: results of the West Japan Thoracic Oncology Group trial (WJOTG0403). Br J Cancer. …

… Gefitinib, an epidermal growth factor receptor (EGFR) … 20% in refractory non–small cell lung
carcinoma. Although female … Seventy patients with relapsed non–small cell lung carcinoma …

… Gefitinib, an oral agent of epidermal growth factor receptor tyrosine kinase inhibitor, has a
… against non-small cell lung cancer (NSCLC). Several predictive factors of gefitinib sensitivity …

… In conclusion, gefitinib treatment as first-line therapy for advanced NSCLC with EGFR
mutations demonstrated promising activity and a good toxicity profile. Randomised phase III trials …

… to identify which patients may respond to gefitinib therapy, we evaluated the association …
NSCLC before starting gefitinib therapy and evaluated their response to gefitinib therapy. This …

… in persons with lung cancer. Many of the principles of management relevant to gefitinib are
distinct … practical guidelines on the use of gefitinib in patients with non–small-cell lung cancer. …

… to predict the tumor response of patients receiving gefitinib for non–small cell lung cancer
(NSCLC). … kinase domain and tumor response and survival in gefitinib-treated NSCLC patients. …

… The ongoing characterization of the molecular abnormalities in non-small-cell lung cancer
has identified potential therapeutic targets. One of these is the epidermal growth factor …